TAMPA, Fla., Dec. 21 /PRNewswire/ -- Romark Laboratories, L.C., a privately-owned biotechnology company, today announced the closing of an $18 million institutional financing with the D.E. Shaw Group.
The proceeds from this financing will enable Romark to advance development of its lead compound, nitazoxanide, for the treatment of hepatitis C, and advance its next-generation thiazolide drug candidates for the treatment of hepatitis B and C and other viral diseases. Romark is currently conducting a U.S. Phase 2 trial of nitazoxanide in hepatitis C patients who have failed standard treatments, and expects to begin a U.S. Phase 2 trial in treatment naive patients in the first quarter of 2008.
About D.E. Shaw Group The D.E. Shaw group (http://www.deshaw.com) is a global investment and technology development firm with more than 1,200 employees; approximately $35 billion in aggregate investment capital; and offices in North America, Europe, and Asia.
About Romark Laboratories
Romark Laboratories, L.C. (http://www.romark.com) is a privately-owned biotechnology company committed to the discovery and development of innovative new small molecules for treating infectious diseases, cancers, and autoimmune diseases.
|SOURCE Romark Laboratories, L.C.|
Copyright©2007 PR Newswire.
All rights reserved